Clinical Trial for Ovarian Cancer (OvaRex®)

Summary

This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety between active and placebo groups.

Timeline

Start

2002-12

Primary completion

—

Completion

2007-12

Drugs

Indications